
Drug Development
Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study
by Leslie Citrome, MD, MPH; Stephanie S. O’Malley, PhD; David
by Leslie Citrome, MD, MPH; Stephanie S. O’Malley, PhD; David
by Ashutosh Kumar, MD; Vikas Pareek, PhD; Muneeb A. Faiq,
by Laetitia Pouzol, MSc, PharmD; Luca Piali, PhD; Claude CA
A message from the editor: Dear Colleagues: Welcome to the
by Ahmed Aboraya, MD, Dr.PH; Henry A. Nasrallah, MD; Daniel
by Niro Kasahara, MD; Mateus L. Matuoka, MD; Katia S.
by Ryan Bart, DO; Waguih William IsHak, MD, FAPA; Shaina
by Evgenia Ivanova, PhD; Anzalee Khan, PhD; Lora Liharska, MS;
By Clare Brennan, DPT, MSPH; Hannah Whillis, MS; Choy Man,
By Benjamin K.P. Woo, MD Funding/financial disclosures: The authors have no